Data protection Impressum

Biotech

Barcelona-based STE Pharmaceuticals plans to convert the former Analytecon plant in Couvet, in the canton of Neuchâtel, into a production site and an R&D department, with completion targeted for 2032.

Catalan pharmaceutical group STE Pharmaceuticals to establish production and R&D in Couvet

3 November 2026

Brazilian encapsulation specialist Nanovetores, backed by Givaudan, is setting up its new headquarters and a production plant in the canton of Bern to serve its European clients more quickly.

Why Nanovetores chose Bern for its new headquarters and production plant

3 November 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (October 2026)

28 October 2026

Alcon, the eye care company headquartered in Geneva, has acquired US biotech Neurotech Pharmaceuticals for USD 550 million in cash, plus potential additional payments tied to milestones.

Alcon has acquired Neurotech for USD 550 million

26 October 2026

WuXi AppTec has opened a new pharmaceutical production line at its site in Couvet, in the canton of Neuchâtel. The USD 100 million investment is part of a broader project to make the site a main production center in Europe for the group.

WuXi AppTec inaugurates a USD 100 million spray-drying line in Couvet

7 October 2026

A new study by BAK Economics shows that the life sciences sector generates CHF 20.6 billion in direct value added in Western Switzerland, and CHF 28.3 billion once its ripple effects across the regional economy are taken into account.

Life sciences generate CHF 28.3 billion in direct value in Western Switzerland

6 October 2026

FluoSphera, the Geneva-based biotech developing advanced in vitro models, has entered a license agreement for Debiopharm's AbYlink antibody conjugation technology, combining it with light sheet microscopy from Leica Microsystems into a single workflow for antibody characterization.

FluoSphera partners with Debiopharm and Leica Microsystems

7 September 2026

Addex Therapeutics, the Geneva-based clinical-stage biotech developing small-molecule allosteric modulators for neurological disorders, has raised gross proceeds of USD 2.8 million through its at-the-market program.

Addex Therapeutics extends its cash runway into the fourth quarter of 2027

31 August 2026

Adaptyv Biosystems has closed a USD 40 million Series A round to expand the automated laboratory it operates for the rapid experimental validation of newly designed proteins.

Adaptyv raises USD 40 million for its automated protein lab

31 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

1 2 3 4 5 … 20